EcoDrugPlus

Cell Division Cycle 7 Homolog (S. Cerevisiae)

Ensembl ID : ENSEEEG00000011427
Gene Symbol: CDC7
4 Cross references
209 Possible Orthologues:

Cellular Tumor Antigen P53-Like

Ensembl ID : ENSEEEG00000020139
Gene Symbol: LOC113577352
3 Cross references
231 Possible Orthologues:

Checkpoint Kinase 1

Ensembl ID : ENSEEEG00000004126
Gene Symbol: CHEK1
4 Cross references
179 Possible Orthologues:

Checkpoint Kinase 2

Ensembl ID : ENSEEEG00000022419
Gene Symbol: CHEK2
4 Cross references
206 Possible Orthologues:

Chemokine (C-C Motif) Receptor 9a

Ensembl ID : ENSEEEG00000015988
Gene Symbol: CCR9A
4 Cross references
190 Possible Orthologues:

Chemokine (C-C Motif) Receptor 9b

Ensembl ID : ENSEEEG00000008055
Gene Symbol: CCR9B
3 Cross references
194 Possible Orthologues:

Chemokine (C-X-C Motif) Receptor 4a

Ensembl ID : ENSEEEG00000022477
Gene Symbol: CXCR4A
4 Cross references
202 Possible Orthologues:

Chemokine (C-X-C Motif), Receptor 4b

Ensembl ID : ENSEEEG00000007578
Gene Symbol: CXCR4B
4 Cross references
205 Possible Orthologues:

Cholecystokinin A Receptor

Ensembl ID : ENSEEEG00000019594
Gene Symbol: CCKAR
2 Cross references
201 Possible Orthologues:

Cholecystokinin B Receptor

Ensembl ID : ENSEEEG00000001169
Gene Symbol: CCKBR
4 Cross references
195 Possible Orthologues:

Cholecystokinin B Receptor A

Ensembl ID : ENSEEEG00000011954
Gene Symbol: CCKBRA
4 Cross references
198 Possible Orthologues:

Cholesterol 24-Hydroxylase-Like

Ensembl ID : ENSEEEG00000007707
Gene Symbol: LOC113586723
3 Cross references
258 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).